GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (LTS:0HF9) » Definitions » PB Ratio

Amicus Therapeutics (LTS:0HF9) PB Ratio : 13.05 (As of Mar. 29, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Amicus Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-29), Amicus Therapeutics's share price is $8.4712. Amicus Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was $0.65. Hence, Amicus Therapeutics's PB Ratio of today is 13.05.

Good Sign:

Amicus Therapeutics Inc stock PB Ratio (=12.99) is close to 2-year low of 12.99.

The historical rank and industry rank for Amicus Therapeutics's PB Ratio or its related term are showing as below:

LTS:0HF9' s PB Ratio Range Over the Past 10 Years
Min: 1.92   Med: 7.81   Max: 36.16
Current: 12.99

During the past 13 years, Amicus Therapeutics's highest PB Ratio was 36.16. The lowest was 1.92. And the median was 7.81.

LTS:0HF9's PB Ratio is ranked worse than
93.06% of 1282 companies
in the Biotechnology industry
Industry Median: 2.385 vs LTS:0HF9: 12.99

During the past 12 months, Amicus Therapeutics's average Book Value Per Share Growth Rate was 18.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -16.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -21.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -14.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Amicus Therapeutics was 50.70% per year. The lowest was -38.30% per year. And the median was -16.20% per year.

Back to Basics: PB Ratio


Amicus Therapeutics PB Ratio Historical Data

The historical data trend for Amicus Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics PB Ratio Chart

Amicus Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.63 10.64 25.31 26.10 14.51

Amicus Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.10 26.55 22.13 17.98 14.51

Competitive Comparison of Amicus Therapeutics's PB Ratio

For the Biotechnology subindustry, Amicus Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amicus Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's PB Ratio falls into.


;
;

Amicus Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Amicus Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=8.4712/0.649
=13.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Amicus Therapeutics  (LTS:0HF9) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Amicus Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amicus Therapeutics Business Description

Traded in Other Exchanges
Address
47 Hulfish Street, Princeton, NJ, USA, 08542
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines